Ventracor chalks up first revenues

By Ruth Beran
Tuesday, 20 September, 2005

Ventracor (ASX:VCR) has received its first revenues, in the form of a cheque from the University of Maryland Medical Centre as payment for a VentrAssist left ventricular assist device (LVAD) recently implanted in a patient as part of its US clinical trial.

The company previously indicated it would reach the milestone before the end of 2005.

Australia's first cases of H5 avian influenza confirmed

Positive results for H5 avian influenza (bird flu) have been confirmed in two seabirds found in...

AusBiotech partners with Tenmile

Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...

Australian CDC issues update in wake of Ebola outbreak

After the WHO determined the outbreak of Ebola in the DRC and Uganda to be a public health...

Content from other channels on our network

Recycling workers' lives at risk from hazardous waste

Biochar used for solar water purification

Climate reporting period closes 30 June — what should businesses do next?

Detoxifying 'super fungi' may recover critical minerals

Training centre opens to improve alloy lifecycle

You see what others miss

Tapping into the labour mobility market to fill ongoing workforce gaps

NSW cracks down on illegal tanning with first two successful prosecutions

Australian hospital workers' mobile phones carry deadly superbugs — study reveals

Bupa to acquire Partnered Health's 68 primary care and three urgent care clinics

Blade innovation reduces the cost of slicing and dicing

Hygienic Design in Practice: Supporting Modern Food Production

Clearer labelling for seafood in hospitality becomes mandatory

Startup moves beyond the lab with alt-dairy ingredient

Australia's fresh produce sector can apply for US study tour